Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

Lars Erik Kristensen, Tore Saxne, Jan-Ake Nilsson, Pierre Geborek, Lars Erik Kristensen, Tore Saxne, Jan-Ake Nilsson, Pierre Geborek

Abstract

The objective of this work is to compare the adherence to therapy of patients receiving etanercept and infliximab during first tumour necrosis factor (TNF)-blocking treatment course in rheumatoid arthritis. Special emphasis is placed on potential predictors for treatment termination and the impact of concomitant methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs). Patients (n = 1,161) with active rheumatoid arthritis, not responding to at least two DMARDs including MTX starting etanercept or infliximab therapy for the first time, were included in a structured clinical follow-up protocol. Information on diagnosis, disease duration, previous and ongoing DMARDs, treatment start and termination, as well as cause of withdrawal was prospectively collected during the period of March 1999 through December 2004. Patients were divided into six groups according to TNF-blocking drugs and concomitant DMARDs. Five-year level (one-year) of adherence to therapy was 36% (69%) for patients receiving infliximab in combination with MTX compared with 65% (89%) for patients treated with etanercept and MTX (p < 0.001). Cox regression models showed that the risk for premature treatment termination of patients treated with infliximab was threefold higher than for etanercept (p < 0.001). Also, the regression analysis showed that patients receiving concomitant MTX had better treatment continuation than patients treated solely with TNF blockers (p < 0.001). Moreover, patients receiving concomitant MTX had superior drug survival than patients receiving other concomitant DMARDs (p < 0.010). The superior effect of MTX was associated primarily with fewer treatment terminations because of adverse events. In addition, the study identifies low C-reactive protein level, high age, elevated health assessment questionnaire score, and higher previous number of DMARDs as predictors of premature treatment termination. In summary, treatment with etanercept has higher adherence to therapy than treatment with infliximab. Concomitant MTX is associated with improved treatment continuation of biologics when compared with both TNF blockers as monotherapy and TNF blockers combined with other DMARDs.

Figures

Figure 1
Figure 1
Number of patients starting anti-tumour necrosis factor (TNF) therapy during the observational period. The figure presents the number of rheumatoid arthritis patients, per quarter, starting infliximab, etanercept, or adalimumab for the first time during the period of 1999 through 2004 in southern Sweden.
Figure 2
Figure 2
Adherence to therapy for patients treated with etanercept. The level of adherence to therapy is shown as the fraction (between 1 and 0) of patients remaining on therapy during the observation period. Withdrawal due to any reason (a), adverse events (b), or failure to treatment (c) is presented separately. The number of patients under observation at each time point is listed at the bottom of the figure. DMARD, disease-modifying antirheumatic drug.
Figure 3
Figure 3
Adherence to therapy for patients treated with infliximab. The level of adherence to therapy is shown as the fraction (between 1 and 0) of patients remaining on therapy during the observation period. Withdrawal due to any reason (a), adverse events (b), or failure to treatment (c) is presented separately. The number of patients under observation at each time point is listed at the bottom of the figure. DMARD, disease-modifying antirheumatic drug.

References

    1. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliot MJ, Woody JN, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>;2-W.
    1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–1939. doi: 10.1016/S0140-6736(99)05246-0.
    1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen J, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–1602. doi: 10.1056/NEJM200011303432202.
    1. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med. 1997;337:141–147. doi: 10.1056/NEJM199707173370301.
    1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann intern Med. 1999;130:478–486.
    1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med. 2000;343:1586–1593. doi: 10.1056/NEJM200011303432201.
    1. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443–1450. doi: 10.1002/art.10308.
    1. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:353–363. doi: 10.1002/art.20019.
    1. Klareskog L, van der HD, de Jager JP, Gough A, Kalden J, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681. doi: 10.1016/S0140-6736(04)15640-7.
    1. Zink A, Listing JD, Kary S, Ramlau P, Stoyanova-Scholz M, babinsky K, von Hineuber U, Gromnica-Ihle E, Wassenberg S, Antoni C, et al. Treatment continuation in patients receiving biologics or conventional DMARD therapy. Ann Rheum Dis. 2005;64:1274–1279. doi: 10.1136/ard.2004.031476.
    1. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793–798. doi: 10.1136/ard.61.9.793.
    1. Geborek P, Nitelius E, Noltorp S, Petri H, Jacobsson L, Larsson L, Saxne T, Leden I. Population based studies of biologic anti-rheumatic drug use in southern Sweden. Comparison with pharmaceutical sales. Ann Rheum Dis. 2005;64:1805–1807. doi: 10.1136/ard.2005.036715.
    1. Van Riel PLCM, van Gestel AM, Scott DL on behalf of the EULAR standing committee for international clinical studies including therapeutic trials . The EULAR Handbook of Clinical Assessment in Rheumatoid Arthritis. Alpen an den Rijn, The Netherlands: Van Zuiden Communications; 2000.
    1. Gomez-Reino JJ, Carmona L, the BIOBADASER Group Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29. doi: 10.1186/ar1881.
    1. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet the inclusion criteria for most recent trials of American College of Rheumatology criteria for remission. J Rheumatol. 2003;30:1138–1146.
    1. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13:16–22. doi: 10.1046/j.1365-2036.1999.00027.x.
    1. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Eng J Med. 2003;348:601–608. doi: 10.1056/NEJMoa020888.
    1. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729–735. doi: 10.1136/ard.60.8.729.
    1. Scallon B, Cai A, Soowski N. Binding and functional comparison of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–426. doi: 10.1124/jpet.301.2.418.
    1. Ziolkowska M, Maslinski W. Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol. 2003;15:267–273. doi: 10.1097/00002281-200305000-00014.
    1. Lugering A, Schmidt M, Lugering N. Infliximab induces apoptosis in monocytes from patients with active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145–1157. doi: 10.1053/gast.2001.28702.
    1. Utley M, Gallivan S, Young A, Cox N, Davies P, Dixey J, Emery P, Gough A, James D, Prouse P, et al. Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies. Rheumatology. 2000;39:1–2. doi: 10.1093/rheumatology/39.1.1.
    1. Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol. 2001;15:139–170. doi: 10.1053/berh.2000.0131.
    1. Wolfe F, Michaud K, DeWitt EM. Why results of clinical trials and observational studies of antitumor necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis. 2004;63:ii13–ii17. doi: 10.1136/ard.2004.028530.
    1. Pincus T, Sokka T. Should Contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis. 2004;63:ii32–ii39. doi: 10.1136/ard.2004.028415.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner